Brilique 90 mg film-coated tablets

Spain
Brand name Brilique 90 mg film-coated tablets
Form tablets, film-coated
Active substance / Dosage
TICAGRELOR · 90 mg
Prescription type Prescription Only Medicine
Registration number 10655004
Manufacturer Astrazeneca Ab
Brilique 90 mg film-coated tablets tablets, film-coated

Patient Information Leaflet

Introduction

Patient Information Leaflet

Brilique 90 mg film-coated tablets

ticagrelor

Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.

  • Keep this leaflet, as you may need to read it again.
  • If you have any questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not give it to other people, even if they have the same symptoms as you, because it may harm them.
  • If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Leaflet Contents

  1. What Brilique is and what it is used for
  2. What you need to know before taking Brilique
  3. How to take Brilique
  4. Possible side effects
  5. How to store Brilique
  6. Contents of the pack and other information

1. What Brilique is and what it is used for

What Brilique is

Brilique contains an active substance called ticagrelor. It belongs to a group of medicines known as antiplatelet agents.

What Brilique is used for

Brilique, in combination with acetylsalicylic acid (another antiplatelet agent), should only be used in adults. This medicine has been prescribed for you because you have had:

  • a myocardial infarction (heart attack), or
  • unstable angina (unstable chest pain or chest discomfort not adequately controlled).

This medicine reduces the risk of having another heart attack, stroke, or dying from a heart or blood vessel-related disease.

How Brilique works

Brilique acts on blood cells called 'platelets' (also known as thrombocytes). These very small blood cells help stop bleeding by clumping together to plug small holes in cut or damaged blood vessels.

However, platelets can also form clots inside damaged blood vessels in the heart and brain. This can be very dangerous because:

  • the clot may completely block blood flow, which can lead to a heart attack (myocardial infarction) or stroke, or
  • the clot may partially block blood vessels leading to the heart; this reduces blood flow to the heart and may cause intermittent chest pain (known as 'unstable angina').

Brilique helps prevent platelets from clumping together. This reduces the likelihood of forming a blood clot that could restrict blood flow.

2. What you need to know before taking Brilique

Do not take Brilique if:

  • You are allergic to ticagrelor or to any of the other ingredients of this medicine (listed in section 6).

  • You are currently experiencing bleeding.

  • You have had a stroke caused by bleeding in the brain.

  • You have severe liver disease.

  • You are taking any of the following medicines:

  • ketoconazole (used to treat fungal infections)

  • clarithromycin (used to treat bacterial infections)

  • nefazodone (an antidepressant)

  • ritonavir and atazanavir (used to treat HIV infection and AIDS)

Do not take Brilique if any of the above apply to you. If you are unsure, consult your doctor or pharmacist before taking this medicine.

Warnings and precautions

Talk to your doctor or pharmacist before taking Brilique if:

  • You have an increased risk of bleeding due to:

  • a recent serious injury

  • a recent surgical procedure (including dental procedures; consult your dentist about this)

  • a disorder affecting blood clotting

  • recent stomach or intestinal bleeding (such as stomach ulcer or colon ‘polyps’)

  • You need to undergo any surgical procedure (including dental procedures) while taking Brilique. This is because your risk of bleeding may increase. Your doctor may decide to stop treatment with this medicine 5 days before surgery.

  • Your heart rate is abnormally slow (usually less than 60 beats per minute) and you do not already have a device implanted to regulate your heart (pacemaker).

  • You have asthma or other lung problems or difficulty breathing.

  • You develop irregular breathing patterns, such as periods of rapid breathing, slow breathing, or brief pauses in breathing. Your doctor will decide whether you need further evaluation.

  • You have had liver problems or a previous illness that may have affected your liver.

  • You have had a blood test showing elevated levels of uric acid.

If any of the above apply to you (or if you are unsure), consult your doctor or pharmacist before taking this medicine.

If you are taking Brilique and heparin:

  • Your doctor may require a blood sample for diagnostic testing if they suspect a rare platelet disorder caused by heparin. It is important that you inform your doctor that you are taking both Brilique and heparin, as Brilique may affect the diagnostic test.

Children and adolescents

Brilique is not recommended for use in children and adolescents under 18 years of age.

Taking Brilique with other medicines

Tell your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines. This is because Brilique may affect how some medicines work, and some medicines may affect Brilique.

Tell your doctor or pharmacist if you are taking any of the following medicines:

  • Rosuvastatin (a medicine used to treat high cholesterol)
  • more than 40 mg daily of simvastatin or lovastatin (medicines used to treat high cholesterol levels)
  • rifampicin (an antibiotic)
  • phenytoin, carbamazepine, and phenobarbital (used to control epileptic seizures)
  • digoxin (used to treat heart failure)
  • cyclosporine (used to suppress the body’s immune defenses)
  • quinidine and diltiazem (used to treat abnormal heart rhythms)
  • beta-blockers and verapamil (used to treat high blood pressure)
  • morphine and other opioids (used to treat acute pain)

In particular, inform your doctor or pharmacist if you are taking any of the following medicines that increase the risk of bleeding:

  • ‘oral anticoagulants’, often referred to as ‘blood thinners’, including warfarin.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), commonly taken as painkillers, such as ibuprofen and naproxen.
  • Selective Serotonin Reuptake Inhibitors (SSRIs), taken as antidepressants, such as paroxetine, sertraline, and citalopram.
  • other medicines such as ketoconazole (used to treat fungal infections), clarithromycin (used to treat bacterial infections), nefazodone (an antidepressant), ritonavir and atazanavir (used to treat HIV infection and AIDS), cisapride (used to treat stomach acid reflux), ergot alkaloids (used to treat migraines and headaches).

Also inform your doctor that, because you are taking Brilique, you may have an increased risk of bleeding if you are given fibrinolytic agents, often called ‘clot dissolvers’, such as streptokinase or alteplase.

Pregnancy and breastfeeding

The use of Brilique is not recommended if you are pregnant or may become pregnant. Women should use appropriate contraceptive methods to prevent pregnancy while taking this medicine.

Consult your doctor before taking this medicine if you are breastfeeding. Your doctor will explain the benefits and risks of taking Brilique during this period.

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before taking this medicine.

Driving and using machines

Brilique is unlikely to affect your ability to drive or operate machinery. However, if you feel dizzy or confused while taking this medicine, take care when driving or using machines.

Sodium content

This medicine contains less than 1 mmol of sodium (23 mg) per dose, i.e., essentially ‘sodium-free’.

3. How to take Brilique

Follow exactly the instructions given by your doctor for taking this medicine. If you are unsure, consult your doctor or pharmacist again.

How much to take

  • The initial dose is two tablets at once (a loading dose of 180 mg). This dose is normally given to you in hospital.
  • After this initial dose, the usual dose is one 90 mg tablet twice daily for 12 months, unless your doctor tells you otherwise.
  • Take this medicine at the same time each day (for example, one tablet in the morning and one at night).

Taking Brilique with other blood-thinning medicines

Your doctor will normally also prescribe acetylsalicylic acid. This is a substance found in many medicines used to prevent blood clotting. Your doctor will tell you how much to take (usually between 75–150 mg daily).

How to take Brilique

  • You may take this medicine with or without food.
  • You can check when you last took a Brilique tablet by looking at the blister pack. A sun (for morning) and a moon (for night) are shown. This will indicate whether you have taken your dose.

If you have difficulty swallowing the tablet

If you have difficulty swallowing the tablet, you may crush it and mix it with water as follows:

  • Crush the tablet into a fine powder
  • Pour the powder into half a glass of water
  • Stir and drink immediately
  • To ensure no medicine is left behind, rinse the empty glass with another half glass of water and drink this

If you are in hospital, the tablet may be administered to you mixed with a small amount of water through a tube inserted into your nose (nasogastric tube).

If you take more Brilique than you should

If you take more Brilique than you should, contact your doctor or go to hospital immediately. Take the medicine pack with you. You may be at increased risk of bleeding.

If you forget to take Brilique

  • If you miss a dose, simply take your next dose at the usual time.
  • Do not take a double dose (two doses at once) to make up for a missed dose.

If you stop taking Brilique

Do not stop taking Brilique without consulting your doctor. Take this medicine regularly and for as long as your doctor tells you to. If you stop taking Brilique, your risk of having another heart attack or stroke, or of dying from a heart or blood vessel-related disease, may increase.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone will experience them. The following adverse effects may occur with this medicine:

Brilique affects blood clotting, so most adverse effects are related to bleeding. Bleeding may occur in any part of the body. Some degree of bleeding is common (such as bruising and nosebleeds). Serious bleeding is rare but can potentially be fatal.

Tell your doctor immediately if you notice any of the following – you may need urgent medical treatment:

  • Bleeding in the brain or within the skull is an uncommon adverse effect, and may cause signs of a stroke such as:

  • sudden numbness or weakness in the arms, legs, or face, especially on one side of the body

  • sudden confusion, difficulty speaking or understanding others

  • sudden difficulty walking, or loss of balance or coordination

  • sudden dizziness or a sudden, severe headache of unknown cause

  • Signs of bleeding such as:

  • severe or uncontrollable bleeding

  • unexpected bleeding or bleeding that lasts a long time

  • pink, red, or brown urine

  • vomiting blood (bright red) or vomit that looks like "coffee grounds"

  • black or red stools (resembling tar)

  • coughing up blood or vomiting blood

  • Fainting (syncope)

  • temporary loss of consciousness due to a sudden drop in blood flow to the brain (common)

  • Signs of a blood clotting disorder called Thrombotic Thrombocytopenic Purpura (TTP), such as:

  • fever and purple spots (called purpura) on the skin or in the mouth, with or without yellowing of the skin or eyes (jaundice), unexplained extreme tiredness, or confusion

Contact your doctor if you notice any of the following:

  • Feeling short of breath – this is very common. This may be due to heart disease or another cause, or it may be a side effect of Brilique. Shortness of breath related to Brilique is usually mild and is characterized by a sudden, unexpected need for air, typically occurring at rest. It may appear during the first weeks of treatment and may resolve in many cases. If you think your shortness of breath has worsened or persists, inform your doctor. Your doctor will decide whether you need treatment or further investigations.

Other possible adverse effects

Very common (may affect more than 1 in 10 people)

  • High level of uric acid in blood (as seen in blood tests)
  • Bleeding due to blood disorders

Common (may affect up to 1 in 10 people)

  • Bruising
  • Headache
  • Dizziness or sensation of spinning
  • Diarrhea or indigestion
  • Feeling unwell (nausea)
  • Constipation
  • Rash
  • Itching
  • Severe pain and swelling in the joints – these are signs of gout
  • Dizziness, lightheadedness, or blurred vision – these are signs of low blood pressure
  • Nosebleeds
  • Heavier than normal bleeding after surgery or cuts (e.g., while shaving) and wounds
  • Bleeding from the stomach lining (ulcer)
  • Bleeding gums

Uncommon (may affect up to 1 in 100 people)

  • Allergic reaction – a skin rash, itching, or swelling of the face, lips, or tongue may be signs of an allergic reaction
  • Confusion
  • Vision problems caused by bleeding in the eye
  • Heavier vaginal bleeding, or bleeding occurring at different times than your usual menstrual period
  • Bleeding into joints and muscles causing painful swelling
  • Blood in the ear
  • Internal bleeding, which may cause dizziness or lightheadedness

Frequency not known (cannot be estimated from available data)

  • Abnormally slow heart rate (usually below 60 beats per minute)

Reporting of adverse effects

If you experience any adverse effects, talk to your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. You can also report them directly through the national reporting system listed in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Brilique

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the blister and on the packaging after EXP/EXP. The expiry date refers to the last day of the month indicated.

This medicine does not require any special storage conditions.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines and packaging that you no longer need. This will help protect the environment.

6. Contents of the container and additional information

Composition of Brilique

  • The active substance is ticagrelor. Each film-coated tablet contains 90 mg of ticagrelor.

  • The other components are:

Tablet core: mannitol (E421), calcium hydrogen phosphate dihydrate, sodium carboxymethyl starch type A, hydroxypropylcellulose (E463), magnesium stearate (E470b).

Film coating of the tablets: hypromellose (E464), titanium dioxide (E171), talc, macrogol 400, yellow iron oxide (E172).

Appearance of the product and contents of the container

Film-coated tablet (tablet): The tablets are round, biconvex, yellow, film-coated, marked with a "90" over a "T" on one side.

Brilique is available in:

  • standard blisters (with sun/moon symbols) in packs of 60 and 180 tablets
  • calendar blisters (with sun/moon symbols) in packs of 14, 56 and 168 tablets
  • pre-cut unit dose blisters in packs of 100x1 tablet

Only certain pack sizes may be marketed.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder:

AstraZeneca AB

SE‑152 57 Södertälje

Sweden

Manufacturer:

AstraZeneca AB

Gärtunavägen

SE‑151 85 Södertälje

Sweden

Further information on this medicinal product is available upon request to the local representative of the Marketing Authorization Holder:

Belgium/Belgium/Belgium

AstraZeneca S.A./N.V.

Tel: +32 2 370 48 11

Lithuania

UAB AstraZeneca Lietuva

Tel: +370 5 2660550

Text in Cyrillic characters on white background with the words Bulgaria, AstraZeneca Bulgaria EOOD and the phone number +359 2 44 55 000

Luxembourg/Luxembourg

NV AstraZeneca SA

Tél/Tel: +32 2 370 48 11

Czech Republic

AstraZeneca Czech Republic s.r.o

Tel: +420 222 807 111

Hungary

AstraZeneca kft

Tel.: +36 1 883 6500

Denmark

AstraZeneca A/S

Tlf: +45 43 66 64 62

Malta

Associated Drug Co. Ltd

Tel: +356 2277 8000

Germany

AstraZeneca GmbH

Tel: +49 40 809034100

Netherlands

AstraZeneca BV

Tel: +31 85 808 9900

Estonia

AstraZeneca

Tel: +372 6549 600

Norway

AstraZeneca AS

Tlf: +47 21 00 64 00

Greece

AstraZeneca A.E.

Tel: +30 2 106871500

Austria

AstraZeneca Österreich GmbH

Tel: +43 1 711 31 0

Spain

AstraZeneca Farmacéutica Spain, S.A.

Tel: +34 91 301 91 00

Poland

AstraZeneca Pharma Poland Sp. z o.o.

Tel.: +48 22 245 73 00

France

AstraZeneca

Tél: +33 1 41 29 40 00

Portugal

AstraZeneca Produtos Farmacêuticos, Lda.

Tel: +351 21 434 61 00

Croatia

AstraZeneca d.o.o.

Tel: +385 1 4628 000

Romania

AstraZeneca Pharma SRL

Tel: +40 21 317 60 41

Ireland

AstraZeneca Pharmaceuticals (Ireland) DAC

Tel: +353 1609 7100

Slovenia

AstraZeneca UK Limited

Tel: +386 1 51 35 600

Iceland

Vistor hf

Tel: +354 535 7000

Slovak Republic

AstraZeneca AB o.z.

Tel: +421 2 5737 7777

Italy

AstraZeneca S.p.A.

Tel: +39 02 00704500

Finland

AstraZeneca Oy

Puh/Tel: +358 10 23 010

Cyprus

Alkem Laboratories Ltd

Tel: +357 22490305

Sweden

AstraZeneca AB

Tel: +46 8 553 26 000

Latvia

SIA AstraZeneca Latvija

Tel: +371 67377 100

United Kingdom (Northern Ireland)

AstraZeneca UK Ltd

Tel: +44 1582 836 836

Date of the most recent revision of this leaflet:

Other sources of information

Detailed information on this medicine is available on the website of the European Medicines Agency: http://www.ema.europa.eu.